Stock Taper
SCREENER COMPARE ANY 2 STOCKS
XLO
XILIO THERAPEUTICS, INC.
NASDAQ
$9.00
▼ DOWN 0.22% (-0.02)

KEY STATISTICS

Market Cap$59.44 M
52w High$12.74
52w Low$6.47
Dividend Yield—
Frequency—
P/E-5.56
Volume7.53K
Shares Out.6.58M

COMPANY

LEADERSHIP

Rene Russo
CHIEF EXECUTIVE
Rene Russo

COMPENSATION 2026

Salary$643,700
Stock Awards$0
Incentive Plan Pay$371,736
All Other Comp.$14,000
Total$6,451,495

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 22, 2021
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
76

PRICE TARGET

Target High$98.00
Target Low$98.00
Target Median$98.00
Target Consensus$98.00

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$4.84M
NOV
5
THU

SPLIT RECORD

DATETYPERATIO
2026-03-16Reverse1:14

PRICE

$9.00 ▼ DOWN 0.22% (−$0.02)
OVERLAYS
$9.00$9.05$9.10$9.159:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM9.00

About Xilio Therapeutics, Inc.

https://www.xiliotx.com ↗

Xilio Therapeutics, a 2016-founded biotech in Waltham, MA, develops immunotherapies like XTX101 and cytokine programs (XTX202, XTX301, XTX401) to enhance cancer immune responses, with several candidates in clinical trials.

INDUSTRY

Biotechnology

A PRODUCT XILIO THERAPEUTICS, INC. IS KNOWN FOR

Vilastobart
Vilastobart

Vilastobart is an investigational tumor-activated anti-CTLA-4 antibody by Xilio, in Phase 2 for metastatic microsatellite stable colorectal cancer, focusing on tumor-selective immuno-oncology therapies.

COMPETITORS

COMPETITOR
AGEN COMPARE
CGEM COMPARE
CRVS COMPARE
HOWL COMPARE
JANX COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
14
LISTED HERE
3
RANKED BY POSITION SIZE
VTS.AX
0.00% · 142.4K
IWC
0.01% · 8.2K
DCOR
0.00% · 1.1K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
100.00%
HOLDERS
51
TOP 12 OF 51 · RANKED BY POSITION SIZE
Gilead Sciences, Inc.
9.1M sh · $5.83M
Bain Capital Life Sciences Investors, LLC
7.4M sh · $4.72M
Frazier Life Sciences Management, L.P.
5.9M sh · $3.79M
Point72 Asset Management, L.P.
4.0M sh · $2.56M
Sio Capital Management, LLC
2.1M sh · $1.37M
Stempoint Capital LP
2.0M sh · $1.3M
Merck & Co., Inc.
1.5M sh · $949.9K
Takeda Pharmaceutical Co Ltd
1.5M sh · $1.24M
Rivervest Venture Management LLC
1.4M sh · $1.14M
Vanguard Group Inc
1.3M sh · $803.64K
Empery Asset Management, LP
1.2M sh · $757.38M
Ghisallo Capital Management LLC
1.1M sh · $712.68K

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
DIRECTOR
Bello Akintunde Olatokumbo
Purchase · 5.0K shares
2026-06-11
★
DIRECTOR
Shannon James Samuel
Purchase · 5.0K shares
2026-06-11
★
DIRECTOR
Curran Daniel J.
Purchase · 5.0K shares
2026-06-11
★
DIRECTOR
Xu Yuan
Purchase · 5.0K shares
2026-06-11

SECTORS PEERS

PEERPRICE
OKUR$3.55COMPARE
ALGS$6.17COMPARE
TVRD$1.88COMPARE
TPST$1.02COMPARE
PDSB$0.22COMPARE
SKYE$1.84COMPARE